Lifecare Innovations

What Lifecare Innovations does

Lifecare Innovations Pvt. Ltd. is an India-based medical biotechnology company founded in 2000 by Dr. Jitendra N. Verma and Dr. Lily Verma, headquartered in Gurugram, Haryana, with manufacturing and a Laboratory of Translational Research in Nanomedicine at Biotech Park, Lucknow. The company specializes in Novel Drug Delivery Systems (NDDS), specifically liposomal and nano-formulation technology, combining Lecithin and Cholesterol with Amphotericin B suspended in Normal Saline 0.9% — a compositional distinction from competitors like AmBisome that use dextrose. Its flagship product, FUNGISOME i.v. (Liposomal Amphotericin B in Saline), was India's first liposomal drug (launched 2003) and remains the world's only Liposomal Amphotericin B in saline, with 300,000+ infusions administered over 17 years and no reported nephrotoxicity, supporting a low effective dose of 1-3 mg/kg/day and broad-spectrum efficacy against Candida, Aspergillus, Mucor (including drug-resistant Candida auris and Candida haemulonii), Cryptococcus, and Visceral Leishmaniasis / PKDL.

The product portfolio spans three categories: Critical Care (FUNGISOME i.v., AmBullet i.v.) for systemic fungal infections; Derma Care (FUNGISOME Gel — the world's first topical liposomal Amphotericin B, Psorisome Gel — the world's first topical liposomal Dithranol, Lipotar S Gel, FenAcheSome Gel) for dermatological applications; and Other Products (POSACONASOL tablets plus azole-class antifungals and the antibacterial Bacteplanin). The company sells primarily to tertiary-care hospitals, infectious disease and dermatology departments, ICUs, and pharmacy chains via direct enterprise sales ([email protected]) supplemented by a network of C&F agents, wholesalers, stockists, and distributors across India. Pricing is quote-based and not publicly disclosed; the GTM motion is driven by peer-reviewed clinical evidence (Phase II 94%, Phase III 90.9%, Phase IV 91.1% efficacy), published trials in journals including Journal of Postgraduate Medicine, Mycoses, J Clin Microbiol, and NEJM, medical conference engagement, and earned media — most notably during the 2021 COVID-19-associated mucormycosis outbreak when Lifecare became the first Indian manufacturer of the Black Fungus treatment.

Name

Lifecare Innovations

Legal name

Lifecare Innovations Pvt Ltd.

Website

https://lifecareinnovations.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Lifecare Innovations is an India-based biotechnology company that develops, manufactures, and markets liposomal and nano-formulation pharmaceuticals (notably FUNGISOME i.v., a saline-based Liposomal Amphotericin B), serving hospitals, infectious disease and dermatology departments, and pharmacy distributors with antifungal and dermatology products across India.

Ownership category

akta.pro rank

Product category

Liposomal Antifungal Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Liposomal drug delivery
• Antifungal pharmaceuticals
• Novel drug delivery systems
• Controlled release pharmaceuticals
• Biopharmaceutical manufacturing

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue is generated through the manufacture and sale of proprietary liposomal pharmaceutical products including FUNGISOME i.v., FUNGISOME Gel, AmBullet i.v., Psorisome Gel, Lipotar S Gel, POSACONASOL tablets, and FenAcheSome Gel. Products are sold directly to hospitals, healthcare institutions, pharmacies, and through distributor/wholesaler networks. Pricing is quote-based and not publicly disclosed.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Lifecare Innovations is a biotechnology pharmaceutical company that develops, manufactures, and markets proprietary liposomal and nano-formulation drug delivery system (NDDS) based pharmaceutical products. Its flagship product, FUNGISOME i.v. (Liposomal Amphotericin B in Saline), is India's first liposomal drug and the world's only liposomal Amphotericin B suspended in saline (vs. dextrose), delivering a nephro-safe, highly effective antifungal for treatment of systemic fungal infections, mucormycosis (black fungus), candidiasis, cryptococcal meningitis, and visceral leishmaniasis. The portfolio spans Critical Care injectables (FUNGISOME i.v., AmBullet i.v.), Derma Care topical gels (FUNGISOME Gel, Psorisome Gel, Lipotar S Gel, FenAcheSome Gel), and other oral antifungals/antibacterials (POSACONASOL, Fungivor, Fungitrace, Funginazole, Derbina, Bacteplanin).

Product overview

Lifecare Innovations is a biotechnology company specializing in Liposomal Drug Delivery System (NDDS) based pharmaceutical products. The company offers a portfolio of products across three main categories: Critical Care (FUNGISOME® i.v., AmBullet® i.v.) for systemic fungal infections and visceral leishmaniasis; Derma Care (FUNGISOME® Gel, Psorisome® Gel, Lipotar™ S Gel, FenAcheSome Gel) for topical dermatological treatments; and Other Products (POSACONASOL® tab., Fungivor®, Fungitrace®, Funginazole™, Derbina™, Bacteplanin®) for additional antifungal and antibacterial therapies. The company's flagship innovation is FUNGISOME® i.v., India's first liposomal product and world's best anti-fungal drug, which uses proprietary liposomal technology to deliver Amphotericin B without nephrotoxicity.

Differentiator

Problem solved

Functional benefit

Brands

• FUNGISOME: Liposomal Amphotericin B product line including FUNGISOME® i.v. (intravenous) and FUNGISOME® Gel (topical) for treatment of systemic and superficial fungal infections including Mucormycosis
• AmBullet
• Psorisome
• Lipotar
• POSACONASOL
• FenAcheSome
• Fungitericin
• Fungivor
• Fungitrace
• Funginazole
• Derbina
• Bacteplanin

Quantifiable outcome

• No nephrotoxicity reported across 300,000+ infusions over 17 years of clinical use
• +5 more outcomes

Named customers2 records

Segments3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Biotech Park, LucknowcoreStrategic or Co-development PartnerBiotech Park, Lucknow is a key operational partner hosting Lifecare Innovations' Manufacturing and Research Center and State-of-the-art Laboratory of Translational Research in Nanomedicine. The Biotech Park also worked to ramp up production of the Black Fungus drug (FUNGISOME) during the 2021 mucormycosis outbreak in India.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cipla: Cipla is one of India's largest pharmaceutical companies with broad antifungal, critical care, and dermatology portfolios including branded and generic azoles and Amphotericin B. Comparable as a broad incumbent operating in the same Indian market segments as Lifecare.
• Biocon: Biocon is an Indian biopharmaceutical company with biologics manufacturing and specialty pharma operations. Comparable as an Indian broad incumbent developing biologics/liposomal platforms and operating in specialty pharmaceutical categories adjacent to Lifecare's.
• Sun Pharmaceutical Industries: Sun Pharma is India's largest specialty pharma company with a deep antifungal portfolio (including liposomal Amphotericin B) and significant dermatology presence. Comparable as a broad incumbent competing across Lifecare's full product range.
• Mylan (now Viatris): Viatris (formerly Mylan) markets generic and branded antifungals globally, including Amphotericin B products. Comparable as a broad incumbent with overlapping antifungal franchise and global distribution reach.
• Pfizer: Pfizer markets a broad antifungal portfolio (including echinocandins and azoles such as voriconazole) globally and in India. Comparable as a broad incumbent with overlapping therapeutic coverage and stronger commercialization infrastructure.

Emerging players

• Pacira BioSciences: Pacira BioSciences specializes in injectable liposomal and non-opioid drug delivery platforms, most notably with DepoFoam technology. Comparable as a peer developing proprietary liposomal/injectable drug delivery systems for specialty therapeutics.

Direct peers

• Bharat Serums and Vaccines: Bharat Serums and Vaccines is an Indian specialty biopharmaceutical company that produces Amphotericin B formulations and other critical care injectables, including competing products in the systemic antifungal segment. Operates in the same Indian specialty injectable market as Lifecare.
• Gilead Sciences: Gilead Sciences markets AmBisome, the incumbent global liposomal Amphotericin B product and Lifecare's primary direct competitor. Both companies compete in the same specialty injectable antifungal category, addressing systemic fungal infections with liposomal formulations.
• Astellas Pharma: Astellas co-markets AmBisome (liposomal Amphotericin B) in certain geographies and is a direct global competitor in the liposomal antifungal category. Competes head-to-head with FUNGISOME in hospitals treating invasive fungal infections and mucormycosis.

Others

• Bristol-Myers Squibb: BMS is a major global pharmaceutical company with infectious disease and specialty therapeutics operations. Comparable as a large specialty pharma adjacent player that could be a strategic acquirer of niche antifungal/liposomal platforms like Lifecare's.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/lifecare2000
• YouTubeyoutube.com/channel/UCbpUE7jHRXeiULofI5fxbdQ
• LinkedInlinkedin.com/company/lifecare-innovations-private-limited
• Instagraminstagram.com/lifecare_innovations

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifecare Innovations